Loading financial data...

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Financial Statements | Global Financial Data

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CRLSEC EDGAR

Services-Commercial Physical & Biological ResearchCIK: 1100682

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$4.1B	$4.0B	$3.5B	$2.9B	$2.6B
Gross Profit	—	—	—	—	—
Selling, General and Administrative Expense	$747.9M	$665.1M	$619.9M	$528.9M	$517.6M
Operating Income (Loss)	$617.3M	$651.0M	$589.9M	$432.7M	$351.2M
Interest Expense	—	—	$73.9M	$86.4M	$60.9M
Other Nonoperating Income (Expense)	$95.5M	$30.5M	-$35.9M	$100.0M	$12.3M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$581.3M	$623.0M	$480.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$7.5B	$8.2B	$7.6B	$7.0B	$5.5B
Assets, Current	$1.4B	$1.6B	$1.4B	$1.3B	$1.2B
Cash and Cash Equivalents, at Carrying Value	$194.6M	$276.8M	$233.9M	$228.4M	$238.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$720.9M	$780.4M	$752.4M	$642.9M	$617.7M
Inventory, Net	$278.5M	$380.3M	$255.8M	$199.1M	$185.7M
Liabilities	$4.0B	$4.5B	$4.6B	$4.4B	$3.3B
Liabilities, Current	$994.1M	$1.1B	$1.1B	$1.0B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$683.9M	$619.6M	$760.8M	$546.6M	$480.9M
Net Cash Provided by (Used in) Investing Activities	-$563.2M	-$607.9M	-$1.4B	-$601.5M	-$681.5M
Net Cash Provided by (Used in) Financing Activities	-$85.5M	-$42.4M	$672.6M	$47.2M	$231.9M
Payments for Repurchase of Common Stock	$24.2M	$38.7M	$40.7M	$24.0M	$18.1M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)